Focus: Augustine Therapeutics is a Belgium-based biotech company focused on therapeutics for neuromuscular diseases, operating as a public entity with a specialized pipeline of rehabilitation and physical intervention programs.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Augustine Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Augustine Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Augustine Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
MitoRx Therapeutics Appoints Clinical & Scientific Advisory Board to Guide the Development of MTRX31 - The Manila Times
MitoRx Therapeutics Appoints Clinical & Scientific Advisory Board to Guide the Development of MTRX31 The Manila Times
Charcot-Marie-Tooth Market - Future Market Insights
Charcot-Marie-Tooth Market Future Market Insights
Charcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsight - PR Newswire
Charcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsight PR Newswire
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo